Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
The subjects of this study are patients with unresectable stage III non‐small cell lungcancer (NSCLC) who have EGFR mutations.
Epistemonikos ID: 2595ae4329a8538cb8c574f1b31e0d887cc7de4c
First added on: Aug 04, 2026